ID
45877
Description
Principal Investigator: Steven A. Rosenberg, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Colonic Neoplasms,Ovarian Neoplasms,Stomach Neoplasms,Cholangiocarcinoma,Pancreatic Neoplasms,Rectal Neoplasms,Esophageal Neoplasms,Colorectal Neoplasms,Endometrial Neoplasms,Paraneoplastic Syndromes, Ocular https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001003 Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer patients. A critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies. In this study, we performed whole exome and RNA-Seq analysis metastases to determine the nature and frequency of somatic mutations.
Lien
Mots-clés
Versions (1)
- 11/6/23 11/6/23 - Simon Heim
Détendeur de droits
Steven A. Rosenberg, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Téléchargé le
November 6, 2023
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs001003 Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs and consent information.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- This subject phenotype table contains subject IDs, cancer histology, age, and gender.
- This data table contains a mapping of samples IDs and SRA accession IDs.
- This sample attributes table contains sample IDs, histological type, analyte type, body site where sample was collected, and tumor status.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs and consent information.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- This subject phenotype table contains subject IDs, cancer histology, age, and gender.
- This data table contains a mapping of samples IDs and SRA accession IDs.
- This sample attributes table contains sample IDs, histological type, analyte type, body site where sample was collected, and tumor status.
C0680251 (UMLS CUI [1,2])
C0439091 (UMLS CUI [1,2])
C0280100 (UMLS CUI [1,2])
C0677930 (UMLS CUI [1,3])
C0027627 (UMLS CUI [1,4])
C0183882 (UMLS CUI [1,5])
C0430027 (UMLS CUI [1,6])
C1522593 (UMLS CUI [1,7])
C0543467 (UMLS CUI [1,8])
C0005558 (UMLS CUI [1,9])
C2936643 (UMLS CUI [1,10])
C1522577 (UMLS CUI [1,11])
C0031809 (UMLS CUI [1,2])
C5445108 (UMLS CUI [1,3])
C4047968 (UMLS CUI [1,4])
C3244099 (UMLS CUI [1,5])
C0162791 (UMLS CUI [1,6])
C0332152 (UMLS CUI [1,7])
C0005558 (UMLS CUI [1,8])
C0543467 (UMLS CUI [1,9])
C0580737 (UMLS CUI [1,2])
C0023416 (UMLS CUI [1,2])
C1512693 (UMLS CUI [1,3])
C0521144 (UMLS CUI [1,2])
C0853904 (UMLS CUI [1,2])
C0442816 (UMLS CUI [1,2])